Illumina Inc. (NASDAQ: ILMN) beat analysts’ forecasts for revenue and earnings in the second quarter of 2019. Despite the beat, shares were down 2.9% in after-market hours on Monday.
Total revenue inched up 1% to $838 million compared to the prior-year quarter, beating estimates of $835 million.
GAAP net income was $296 million, or $1.99 per share, compared to $209 million, or $1.41 per share, in the year-ago quarter. Adjusted net income was $200 million, or $1.35 per share, ahead of forecasts of $1.34 per share.
Gross margin dipped to 68.4% from 69.3% last year. Adjusted gross margin was 69.5% compared to 70.3% in the prior-year period. R&D expenses rose 9% year-over-year to $166 million.
Francis deSouza, President and CEO said, “In addition to continued sequencing consumables growth, we are encouraged by the sequential and year-over-year growth in shipments across our high, mid, and low-throughput sequencing system portfolio, including a record number of NextSeq Dx systems, reflecting the growing clinical opportunity.”
During the quarter, Illumina launched Veriseq NIPT v2, enabling a genome-wide screen which almost doubles the detection of chromosomal abnormalities. The company also partnered with AnchorDx, a molecular diagnostics company, to develop clinical oncology products for the Chinese market.
For the full year of 2019, Illumina expects revenues to grow approx. 6%. GAAP EPS is expected to be $6.41 to $6.51 and adjusted EPS is estimated to be $6.00 to $6.10.
Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a
PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the
With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,